



ImmuPharma PLC  
("ImmuPharma" or the "Company")

**ImmuPharma to present live on 'Investor Meet Company' platform  
Friday 20 March 2026 @ 12:00 (GMT)**

ImmuPharma PLC (LSE AIM:), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics is pleased to announce that ImmuPharma's Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation relating to the Company's announcement, released on Tuesday 17 March 2026, titled:

**P140 Update - remains on track for licensing deal in 2026  
Accelerated Development of Kapiglucagon for Type 1 Diabetes  
Subscription & WRAP Retail Offer to raise up to £7.5 million**

<https://www.immupharma.co.uk/investors/regulatory-news/>

The live presentation, via the 'Investor Meet Company' platform, will be held on Friday 20 March 2026 @ 12:00 (GMT).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard until 19 March 2026, 09:00am (GMT), or at any time during the live meeting. No new material will be shared at this presentation.

Investors can sign up to Investor Meet Company for free and add to meet ImmuPharma PLC via: <https://www.investormeetcompany.com/immupharma-plc/register>.

Investors who already follow ImmuPharma PLC on the Investor Meet Company platform, will automatically be invited.

The presentation will also be available post the live meeting, on ImmuPharma's website: <https://www.immupharma.co.uk/updates/interviews/>.

Ends

For further information please contact:

<b>ImmuPharma PLC</b> ( <a href="http://www.immupharma.co.uk">www.immupharma.co.uk</a> )	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer and Chairman	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	
<b>Stanford Capital Partners (Joint Broker)</b>	+44 (0) 203 650 3650/51
Patrick Claridge, Bob Pountney	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	

## Notes to Editors

### About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

### About Investor Meet Company

Investor Meet Company provides a digital platform that enables individual investors and wealth managers to access live, interactive presentations by UK-listed companies, regardless of their shareholding, size or location. For more information go to: <https://www.investormeetcompany.com>.

### About RNS REACH Announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.